Tab Application Banner
  • Users Online: 111
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate

Apsangikar Prasad, Chaudhry Sunil, Naik Manoj, Deoghare Shashank, Joseph Jamila

Year : 2018| Volume: 13| Issue : 2 | Page no: 84-89

   This article has been cited by
 
1 Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
Shubhadeep Sinha,Biswadip Ghosh,Syamasis Bandyopadhyay,Firdaus Fatima,Vamsi Krishna Bandi,Pankaj Thakur,Bala Reddy,Sreenivasa Chary,Leela Talluri,Ajay Gupta,Amit Ramchandra Kale,Anil Kumar Gupta,Ashok Kumar P,Diwakar Reddy,Younus Mohammed,Soma Shekar,Sudheer T,Vijay G. Goni,Vishnu Sharma,Vishwanath Yeligod
BMC Rheumatology. 2020; 4(1)
[Pubmed]  [Google Scholar] [DOI]

 

Read this article